TNYA trades 173.7% below Wall Street's consensus target of $2.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TNYA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Tenaya Therapeutics, Inc. (TNYA) has a Wall Street consensus price target of $2.00, based on estimates from 6 covering analysts. With the stock currently trading at $0.70, this represents a potential upside of +173.7%. The company has a market capitalization of $117M.
Analyst price targets range from a low of $2.00 to a high of $2.00, representing a 0% spread in expectations. The median target of $2.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TNYA trades at a trailing P/E of -1.2x. Analysts expect EPS to grow +26.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
RCKTRocket Pharmaceuticals, Inc. | $378M | $3.46 | $5.00 | +49.3% | Buy | — | 19 |
SGMOSangamo Therapeutics, Inc. | $73M | $0.17 | $7.25 | +3927.8% | Hold | — | 14 |
EDITEditas Medicine, Inc. | $274M | $2.80 | $5.00 | +85.9% | Buy | — | 25 |
NTLAIntellia Therapeutics, Inc. | $1.8B | $15.75 | $26.13 | +66.8% | Buy | — | 39 |
BEAMBeam Therapeutics Inc. | $3.7B | $35.53 | $48.00 | +40.6% | Buy | — | 27 |
CRSPCRISPR Therapeutics AG | $5.2B | $54.36 | $71.67 | +32.5% | Buy | — | 38 |
ARWRArrowhead Pharmaceuticals, Inc. | $11.6B | $82.00 | $84.00 | +2.7% | Buy | — | 21 |
FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
RAREUltragenyx Pharmaceutical Inc. | $2.9B | $29.03 | $48.36 | +76.2% | Buy | — | 33 |
SRPTSarepta Therapeutics, Inc. | $1.9B | $17.65 | $25.14 | +43.4% | Buy | 5.0x | 54 |
Quick answers to the most common questions about buying TNYA stock.
The consensus Wall Street price target for TNYA is $2, representing 173.7% upside from the current price of $0.7. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TNYA has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $2 implies 173.7% upside from current levels.
TNYA's current price is $0.7 with a consensus target of $2 (173.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $2 for TNYA, while the most conservative target is $2. The consensus of $2 represents the median expectation. These targets typically reflect 12-month expectations.
TNYA is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TNYA stock forecast based on 6 Wall Street analysts shows a consensus price target of $2, with estimates ranging from $2 (bear case) to $2 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TNYA, with a "Buy" consensus rating and $2 price target (173.7% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TNYA analyst price targets range from $2 to $2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $2 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.